Wyeth - Top 13 Ad Budgets
Company: Wyeth 
2007 Ad Spending: $1.078 billion
2006 Ad Spending: $1.051 billion
Breakdown
- Magazines: $94.7 million
- Newspaper: $9.1 million
- Outdoor: $400,000
- TV: $296.4 million
- Radio: $19.8 million
- Internet: $14.7 million
Where Wyeth is spending money: While other companies spent big on direct to consumer advertising, Wyeth took the more indirect approach. The company spent $16.7 million promoting KnowMenopause.com, a website educating women about menopause and the company's HRT drug. It also shelled out $13.7 million on Yourtimeforchange.com, a website that discusses depression and treatment options (Yourtimforchange.com is no longer on the web).
Web aside, $59.6 million was spent on promoting Wyeth's biologic Enbrel, which treats rheumatoid arthritis, among other ailments. The most money by far ($114M) went to Advil advertising. Wyeth also boosted the vitamin brand Centrum's budget 44.5 percent. The biggest jump, however, was for the hormone replacement therapy Prempro, which saw a spending increase of 249 percent.
Where Wyeth isn't spending money: Enbrel advertising dropped 14.7 percent in 2007. Like many other drugmakers, Wyeth's image advertising dropped significantly, falling 63 percent.
Comments
You have an EMBRIL TV add in which a young woman says "I DIDN'T KNOW IT COULD ATTACK YOUR JOINTS!"
What ignoramus, medically trained or not, dreamed up that stupid statement.
A person with 'rheumatoid arthritis' suffered from joing problems long before the diagnosis was made. ARTHRITIS translates "inflamations of the JOINTS" Fire the joker that dreamed this one up!
W. Zahn, M. D. Long Beach, CA 86-year-old arthritic.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




